Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (291-300 of 567) with videos related to

Pageof 57
Sort By:
Circulation|May 1, 1984
Clinical characteristics and long-term survival of patients with variant anginaD B Mark, R M Califf, K G Morris, et al.
Circulation|February 15, 1996
Relation between activated clotting time during angioplasty and abrupt closureC R Narins, W B Hillegass, C L Nelson, et al.
Journal of Clinical Epidemiology|March 1, 1993
Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgeryR A Dudley, F E Harrell, L R Smith, et al.
American Heart Journal|April 1, 1997
The natural history of single-vessel chronic coronary occlusion: a 25-year experienceJ A Puma, M H Sketch, J E Tcheng, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Annals of Internal Medicine|July 11, 1992
Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarctionJ E Tcheng, J D Jackman, C L Nelson, et al.
Journal of the American College of Cardiology|July 1, 1997
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.
Coronary Artery Disease|July 1, 1994
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupS G Ellis, A M Lincoff, B S George, et al.
American Heart Journal|October 31, 2001
Advanced coronary artery disease: Appropriate end points for trials of novel therapiesD E Kandzari, L C Lam, E L Eisenstein, et al.
American Heart Journal|May 29, 2001
Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRSTM R Shah, S S Stinnett, S E McNulty, et al.
Pageof 57

Showing results (291-300 of 567) with videos related to

Sort By:
Pageof 57
Circulation|May 1, 1984
Clinical characteristics and long-term survival of patients with variant anginaD B Mark, R M Califf, K G Morris, et al.
Circulation|February 15, 1996
Relation between activated clotting time during angioplasty and abrupt closureC R Narins, W B Hillegass, C L Nelson, et al.
Journal of Clinical Epidemiology|March 1, 1993
Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgeryR A Dudley, F E Harrell, L R Smith, et al.
American Heart Journal|April 1, 1997
The natural history of single-vessel chronic coronary occlusion: a 25-year experienceJ A Puma, M H Sketch, J E Tcheng, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Annals of Internal Medicine|July 11, 1992
Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarctionJ E Tcheng, J D Jackman, C L Nelson, et al.
Journal of the American College of Cardiology|July 1, 1997
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic ComplicationsA M Lincoff, R M Califf, K M Anderson, et al.
Coronary Artery Disease|July 1, 1994
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupS G Ellis, A M Lincoff, B S George, et al.
American Heart Journal|October 31, 2001
Advanced coronary artery disease: Appropriate end points for trials of novel therapiesD E Kandzari, L C Lam, E L Eisenstein, et al.
American Heart Journal|May 29, 2001
Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRSTM R Shah, S S Stinnett, S E McNulty, et al.
Pageof 57